# Merestinib In Non-Small Cell Lung Cancer And Solid Tumors

> **NCT02920996** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 12 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Solid Tumor

## Interventions

- **DRUG:** Merestinib

## Key facts

- **NCT ID:** NCT02920996
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-11
- **Primary completion:** 2021-10
- **Final completion:** 2023-10
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Funding was pulled
- **Last updated:** 2024-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02920996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02920996, "Merestinib In Non-Small Cell Lung Cancer And Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02920996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*